Clot burden and comorbidity in natural history of untreated pulmonary thromboembolism: autopsy data in the trial by Barritt and Jordan.

1 Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123:128–135 2 Truitt TJ, Witko J, Kotter S, et al. Levalbuterol reduces total and breakthrough treatments in hospitalized patients [abstract]. Am J Respir Crit Care Med 2000; 161:A553 3 Academy of Managed Care Pharmacy. Format for formulary submissions, version 2.0. Available at: http://www.fmcpnet.org/data/resource/formatv20.pdf. Accessed July 28, 2003 4 Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Costeffectiveness in health and medicine. New York, NY: Oxford University Press, 1996 5 Asmus MJ, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Pharmacotherapy 2000; 20:123–129 6 Asmus MJ, Hendeles L, Weinberger M, et al. Levalbuterol has not been established to have therapeutic advantage over racemic albuterol [letter]. J Allergy Clin Immunol 2002; 110:325 7 Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma [letter]. J Allergy Clin Immunol 2002; 110:324 8 Milgrom H, Skoner D, Bensch G, et al. Author reply [letter]. J Allergy Clin Immunol 2002; 110:325–328